Business Context and Reporting Period
Pliant Therapeutics, Inc. (PLRX) filed a Form 8-K on August 11, 2026, to announce financial results for the second quarter ended June 30, 2026. The company is incorporated in Delaware and trades on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text.
Material Changes
The filing text does not provide data to compare current period results against the prior comparable period. No specific material changes are detailed in the body of this 8-K.
Guidance, Outlook, and Risks
The filing references a press release containing the results but does not include management commentary, forward-looking guidance, specific risks, contingencies, or unusual items within the provided text. The report explicitly states that the information furnished is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for actual Q2 2026 financial figures.
- Verify cash runway and burn rate given the absence of liquidity data in the 8-K summary.
- Confirm any updates to clinical trial timelines or regulatory milestones mentioned in the full press release.
- Check for any new debt covenants or financing activities not detailed in this filing.